Security key
867781304
- Security type / class
- Equity / 0
- Total 13F shares
- 18
- Total 13F value
- $1
- Share change
- 0
- SEC-reported price per share
- $0.06
- Number of holders
- 1
Report period
Q1 2024
Institutions
1
Top holders
1
SBFM full security history
Ownership snapshot
Full 13F holder table
Sunshine Biopharma Inc. SEC filings
Sunshine Biopharma Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SBFM - SUNSHINE BIOPHARMA INC COM NEW - 0 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Malek Chamoun
Disclosed value leader
Malek Chamoun
Comparable rows
0/15
Latest evidence
04 Mar 2024
3/4/5
13F
Highest disclosed value: $2,824,950
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Malek Chamoun has the largest disclosed position value at $2.82M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Malek Chamoun's linked filing trail.
Disclosed position value
Top 5
Malek Chamoun
$2.82M
Steve N. Slilaty
$13K
ARMISTICE CAPITAL, LLC
$578.3K
Rabi Kiderchah
$248.1K
James Daniel Kish
$221.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Malek Chamoun |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$2,824,950
3,700,000 shares
|
— | 20 Oct 2022 |
| Steve N. Slilaty |
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
—
denominator unverified
|
$13,000
130,000 shares
|
— | 04 Mar 2024 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
—
denominator unverified
|
$578,295
2,130,000 shares
|
— | 31 Dec 2023 |
| Rabi Kiderchah |
3/4/5
Director
|
—
denominator unverified
|
$248,138
325,000 shares
|
— | 31 Oct 2021 |
| James Daniel Kish |
3/4/5
Director
|
—
denominator unverified
|
$221,110
289,600 shares
|
— | 31 Oct 2021 |
| Camille Sebaaly |
3/4/5
CFO/Secretary
|
—
denominator unverified
|
$133,204
174,465 shares
|
— | 30 Nov 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
18
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
1
Q1 2024 holders
1
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|